Prognostic tool to predict relapse in visceral leishmaniasis patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to develop a prognostic score to predict relapse in patients suffering from visceral leishmaniasis (VL) in Ethiopia. By conducting a comprehensive clinical and laboratory characterization of confirmed VL patients before and during treatment, the study seeks to identify key factors that influence patient prognosis. Understanding these factors will enable healthcare providers to stratify patients based on their risk of relapse, allowing for tailored monitoring and treatment strategies. The ultimate goal is to improve patient outcomes and reduce morbidity and mortality associated with VL.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* clinically or parasitologically confirmed VL

Exclusion Criteria:

* Age under 12 years
* VL patients already on treatment for 3 days or more
* Severe critical condition or other circumstances that make the study medically inadvisable
* Unlikely to adhere to follow up visits during the study period (e.g. patients who live or work very far away) AND not reachable by phone for follow-up information
* Pregnant or lactating woman

Where it's running

• University of Gondar
  Gonder, Ethiopia Recruiting

Study contacts

• Principal investigator: Eleni Ayele, MD — University of Gondar
• Study coordinator: Saskia van Henten, MD
• Email: svanhenten@itg.be
• Phone: +32(0)32476556

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Recurrent visceral leishmaniasis in people living with HIV

  This project will follow adults living with HIV who develop visceral leishmaniasis to see if differences in the patient or the parasite explain why some people have repeated relapses.

  Recruiting Institute of Tropical Medicine, Belgium · Gonder · NCT07487350

• Eliminating Gambiense sleeping sickness using a single-dose oral treatment in screened seropositive people

  This trial tests whether giving a single dose of acoziborole to people who test positive in screening for Gambiense human African trypanosomiasis can reduce disease transmission over three years.

  Recruiting Phase 3 Institute of Tropical Medicine, Belgium · Bwamanda · NCT07789743

• Immunogenicity screening of Leishmania vaccine candidate antigens in Ethiopian patients

  This study tests whether six Leishmania vaccine candidate antigens can trigger T-cell responses in patients with cutaneous or visceral leishmaniasis.

  Recruiting at 2 sites Institute of Tropical Medicine, Belgium · Addis Ababa and 1 other locations · NCT07783243

• Baseline skin memory T cells in unvaccinated volunteers

  This study tests the natural baseline levels of skin-resident memory T cells in healthy people who have not received the yellow fever vaccine.

  Recruiting Institute of Tropical Medicine, Belgium · Antwerp · NCT07636551

• Improving care and surveillance of fevers in the DRC

  This project tracked people with recent fevers at two hospitals in the DRC to see what causes their fevers, how they are treated, and whether biomarkers like CRP relate to outcomes and antibiotic use.

  Recruiting Institute of Tropical Medicine, Belgium · Kinshasa · NCT07345286

• Controlling Aedes mosquitoes in Kinshasa

  This study is testing different ways to control Aedes mosquitoes in Kinshasa to see if it helps reduce the spread of diseases like dengue and chikungunya.

  Recruiting Institute of Tropical Medicine, Belgium · Kinshasa, République Démocratique Du Congo · NCT06981442

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.